Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices

Pineda, Henry Reyes; Carlson, Matthew J.; Devor, Eric J.; Zhang, Yuping; Thiel, Kristina W.; Samuelson, Megan I.; McDonald, Megan; Yang, Shujie; Stephan, Jean-Marie; Savage, Erica C.; Dai, Donghai; Goodheart, Michael J.; Leslie, Kimberly K.

doi:10.1016/j.ygyno.2015.10.023

Cited by 19 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forkhead transcription factor 1 (FOXO1) is a member of the FOX transcription factor family which regulates a variety of important cellular processes including metabolism, cellular differentiation, apoptosis, and cell cycle progression . FOXO1 expression is associated with endometrial cancer progression in patients receiving progestin therapy . FOXO1 overexpression inhibits endometrial cancer cell proliferation, migration, and invasion .…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA LINC00261 regulates endometrial carcinoma progression by modulating miRNA/FOXO1 expression

Fang

Sang

2018

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA LINC00261 regulates endometrial carcinoma progression by modulating miRNA/FOXO1 expression

Fang

Sang

2018

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Regarding risk of bias within study assessment, for the “Patient selection” domain, three studies were considered to be low risk of bias and 10 were considered unclear risk (because they did clearly not state that patients were consecutive and/or that only cancers with initial myometrial invasion were excluded).…”

Section: Resultsmentioning

confidence: 99%

“…For the “Reference test” domain, nine studies were considered low risk, three studies unclear risk and one study high risk (not differentiating between regression and persistence of disease).…”

Section: Resultsmentioning

confidence: 99%

“…In particular, most studies focused on the estrogen receptor (ER) and progesterone receptor (PR), whose expression is easily assessable by immunohistochemistry . Estrogens are indeed involved in the development of EH and EC, and progestins mediate their action through PR .…”

Section: Introductionmentioning

confidence: 99%

“…[9][10][11] In particular, most studies focused on the estrogen receptor (ER) and progesterone receptor (PR), whose expression is easily assessable by immunohistochemistry. [12][13][14][15][16][17][18][19][20][21][22][23][24] Estrogens are indeed involved in the development of EH and EC, and progestins mediate their action through PR. 2,12 In spite of this, results are conflicting and the possible predictive role of ER and PR is still undefined.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta‐analysis

Raffone

Travaglino

Saccone

et al. 2019

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Introduction Progestins are used as conservative treatment of endometrial hyperplasia (EH) and early endometrial cancer (EEC). We aimed to assess whether immunohistochemical expression of estrogens and progesterone receptors (ER and PR) predicts the treatment response. Material and methods Electronic databases were searched for studies assessing ER and PR expression in EH and EEC treated with progestins. Relative risk for poor response, sensitivity, specificity, diagnostic odds ratio positive and negative likelihood ratios (LR+ and LR−) and area under the curve (AUC) on summary receiver operating characteristic curve were calculated. Subgroup analyses were based on administration route (oral progestin or levonorgestrel‐intrauterine device) and on histological diagnosis (atypical EH/EEC or non‐atypical EH). Only high accuracy (AUC > 0.9; LR+ >10; LR− <0.1) was considered determining for the clinical practice. Results Thirteen studies with 635 patients were included in the systematic review. Studies at high risk of bias were excluded from the meta‐analysis. Negative ER expression did not significantly predict poor response (P = 0.16), with low predictive accuracy (AUC = 0.637). Negative PR significantly predicted poor response (P = 0.01), with moderate accuracy (AUC = .806). In the oral progestin subgroup, neither ER (P = 0.55) nor PR (P = 0.18) had significant predictive value. In the levonorgestrel‐intrauterine device subgroup, both ER (P < 0.0001) and PR (P = 0.02) were significantly predictive of good response, although the accuracy was suboptimal (LR+ 6.02 and 2.48, respectively; LR− 0.59 and 0.55, respectively). The atypical EH/EEC subgroup showed non‐significant results. Data about non‐atypical EH were not extractable. Conclusions ER and PR expressions are significantly predictive of response in EH and EEC treated with a levonorgestrel‐intrauterine device but not with oral progestins. However, their accuracy is insufficient to be determining in the clinical practice.

show abstract

Particles and Prejudice: Nanomedicine Approaches to Reducing Health Disparities in Endometrial Cancer

Rowlands,

Folberg,

Beickman

et al. 2023

Small

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecological malignancy worldwide and unfortunately has a much higher mortality rate in Black women compared with White women. Many potential factors contribute to these mortality rates, including the underlying effects of systemic and interpersonal racism. Furthermore, other trends in medicine have potential links to these rates including participation in clinical trials, hormone therapy, and pre‐existing health conditions. Addressing the high incidence and disparate mortality rates in endometrial cancer requires novel methods, such as nanoparticle‐based therapeutics. These therapeutics have been growing in increasing prevalence in pre‐clinical development and have far‐reaching implications in cancer therapy. The rigor of pre‐clinical studies is enhanced by the likeness of the model to the human body. In systems for 3D cell culture, for example, the extracellular matrix mimics the tumor more closely. The increasing emphasis on precision medicine can be applied to cancer using nanoparticle‐based methods and applied to pre‐clinical models by using patient‐derived model data. This review highlights the intersections of nanomedicine, precision medicine, and racial disparities within endometrial cancer and provides insights into reducing health disparities using recent scientific advances on the nanoscale.

show abstract

Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices

Cited by 19 publications

References 33 publications

Long noncoding RNA LINC00261 regulates endometrial carcinoma progression by modulating miRNA/FOXO1 expression

Long noncoding RNA LINC00261 regulates endometrial carcinoma progression by modulating miRNA/FOXO1 expression

Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta‐analysis

Particles and Prejudice: Nanomedicine Approaches to Reducing Health Disparities in Endometrial Cancer

Contact Info

Product

Resources

About